P2RY12 and acute coronary syndrome: In the setting of acute coronary syndrome and a high bleeding risk, the use of the P2Y12 inhibitor or aspirin monotherapy after a short period of dual-antiplatelet therapy (DAPT), or the early shift from newer P2Y12 inhibitors to clopidogrel, are considered potential strategies to reduce the bleeding risk [192,193].